Geovax covid-19 vaccine clinical data presented at world vaccine congress

Presentation of data from phase 2 open-label study of geo-cm04s1 next-generation covid-19 vaccine demonstrates potent antibody and  cellular immunity in immunocompromised patients atlanta, ga, nov. 28, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from the active development program for its next-generation covid-19 vaccine (geo-cm04s1), including phase 2 clinical trial data. the data include some of which was recently published in the journal vaccines and can be accessed here:  geo-cm04s1 publication.
GOVX Ratings Summary
GOVX Quant Ranking